Oxaliplatin Stada

Oxaliplatin, the active ingredient in Oxaliplatin Stada, is a platinum‑based chemotherapy presented as a sterile solution for intravenous use. It is employed in the treatment of colorectal cancer, typically in combination with other agents, and is administered to adult patients under specialist supervision.

GNH USA supplies Oxaliplatin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin is a platinum‑based chemotherapeutic that interferes with DNA replication in rapidly dividing cells. - Colorectal cancer: improves progression‑free survival when used in combination regimens. - Gastric cancer: contributes to tumor response as part of multi‑drug protocols. - Pancreatic cancer: adds cytotoxic effect within combination therapy schedules.

Oxaliplatin may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly reported during infusion. - Peripheral neuropathy: tingling or numbness in extremities, often dose‑related. - Diarrhea: loose stools occurring during or after treatment cycles. - Fatigue: general tiredness that may affect daily activities. - Myelosuppression: reduced blood cell counts, increasing infection risk.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: including anaphylaxis, requiring immediate medical attention. - Acute pulmonary toxicity: respiratory distress or infiltrates on imaging. - Severe neutropenia or thrombocytopenia: markedly low white‑cell or platelet counts. - Cardiac arrhythmias: irregular heart rhythms observed during infusion. - Renal impairment: acute kidney injury in susceptible patients.

When handling Oxaliplatin Stada, clinicians should observe several safety measures to protect patients and staff. - Renal function assessment: evaluate baseline creatinine and monitor during therapy. - Neuropathy monitoring: assess sensory changes before each cycle and adjust dose if needed. - Hematologic surveillance: perform regular complete blood counts to detect myelosuppression. - Infusion site care: rotate sites and observe for phlebitis or extravasation. - Pregnancy and lactation: avoid use in pregnant or breastfeeding women unless benefits outweigh risks. - Store at ambient temperature: keep vials in original packaging, protect from light and moisture.

Oxaliplatin can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Aminoglycoside antibiotics: may increase nephrotoxic potential. - High‑dose vitamin C: can reduce platinum‑drug cytotoxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants: heightened bleeding risk due to thrombocytopenia.\n- Other neurotoxic agents (e.g., vincristine): may exacerbate peripheral neuropathy. - CYP‑inducing agents: potential alteration of drug clearance, requiring dose review. - Radiotherapy: concurrent use may amplify tissue toxicity. - Electrolyte imbalances (hypomagnesemia): can worsen neurotoxic effects.